Sci-Sat AM: Brachy - 11: Improving treatment planning for I-125 lung brachytherapy using Monte Carlo methods

¹²⁵ I brachytherapy used in conjunction with sublobar resection to treat stage I non-small cell lung cancer has been reported to improve disease-free and overall survival rates compared with resection alone. Treatments are planned intra-operatively using seed spacing nomograms or tables to achieve a prescription dose defined 5 mm above the implant plane. Dose distributions for patients treated with this technique at the Mayo Clinic Rochester were reanalyzed using a Monte Carlo (MC) calculation; significant differences were observed between the standard TG-43 dose calculations and the actual dose delivered as determined by MC. This work investigates differences between TG-43 calculated prescription doses and those calculated in more accurate models. Monte Carlo calculations are performed using the EGSnrc user-code BrachyDose with a number of lung tissue phantom models including patient CT-derived phantoms. Seed spacing nomograms using these models are recalculated by determining the dose to the prescription point using the activities per seed required to produce a prescription dose of 100 Gy with the TG-43 point source formalism. Models using nominal density lung or CT-derived density lung tissue result in a significant increase in dose to the prescription point (up to approximately 25%) compared to TG-43 calculated doses. The differences observed suggest that patients routinely receive significantly higher doses than planned using TG-43 derived nomograms. Additionally, deviation from TG-43 increases as seed spacing increases. Media heterogeneities significantly affect dose distributions and prescription doses for ¹²⁵ I lung brachytherapy, underlining the importance of using model-based dose calculation algorithms to plan and analyze these treatments.